Literature DB >> 14742195

In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae.

S Pereyre1, C Guyot, H Renaudin, A Charron, C Bébéar, C M Bébéar.   

Abstract

Macrolide-resistant mutants of Mycoplasma pneumoniae were selected in vitro from the susceptible reference strain M129, by 23 to 50 serial passages in subinhibitory concentrations of macrolides and related antibiotics, erythromycin A, azithromycin, josamycin, clindamycin, quinupristin, quinupristin-dalfopristin, pristinamycin, and telithromycin. Mutants for which the MICs are increased could be selected with all antibiotics except the streptogramin B quinupristin. Portions of genes encoding 23S rRNA (domains II and V) and ribosomal proteins L4 and L22 of mutants were amplified by PCR, and their nucleotide sequences were compared to those of the susceptible strain M129. No mutation could be detected in domain II of 23S rRNA. Two point mutations in domain V of 23S rRNA, C2611A and A2062G, were selected in the presence of erythromycin A, azithromycin, josamycin, quinupristin-dalfopristin, and telithromycin. Mutants selected in the presence of clindamycin and telithromycin harbored a single amino acid change (H70R or H70L, respectively) in ribosomal protein L4, whereas insertions of one, two, or three adjacent glycines at position 60 (M. pneumoniae numbering) were selected in the presence of both streptogramin combinations. Telithromycin was the sole antibiotic that selected for substitutions (P112R and A114T) and deletions ((111)IPRA(114)) in ribosomal protein L22. Three sequential mutational events in 23S rRNA and in both ribosomal proteins were required to categorize the strain as resistant to the ketolide. Azithromycin and erythromycin A were the only selector antibiotics that remained active (MICs, 0.06 and 1 micro g/ml, respectively) on their mutants selected after 50 passages.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742195      PMCID: PMC321523          DOI: 10.1128/AAC.48.2.460-465.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae.

Authors:  F Depardieu; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 2.  Macrolide resistance conferred by base substitutions in 23S rRNA.

Authors:  B Vester; S Douthwaite
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

3.  Molecular typing of Mycoplasma pneumoniae strains by PCR-based methods and pulsed-field gel electrophoresis. Application to French and Danish isolates.

Authors:  A Cousin-Allery; A Charron; B de Barbeyrac; G Fremy; J Skov Jensen; H Renaudin; C Bebear
Journal:  Epidemiol Infect       Date:  2000-02       Impact factor: 2.451

4.  The complete atomic structure of the large ribosomal subunit at 2.4 A resolution.

Authors:  N Ban; P Nissen; J Hansen; P B Moore; T A Steitz
Journal:  Science       Date:  2000-08-11       Impact factor: 47.728

5.  The polypeptide tunnel system in the ribosome and its gating in erythromycin resistance mutants of L4 and L22.

Authors:  I S Gabashvili; S T Gregory; M Valle; R Grassucci; M Worbs; M C Wahl; A E Dahlberg; J Frank
Journal:  Mol Cell       Date:  2001-07       Impact factor: 17.970

6.  Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides.

Authors:  Anne-Laure Prunier; Brigitte Malbruny; Didier Tandé; Bertrand Picard; Roland Leclercq
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

7.  In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae.

Authors:  T A Davies; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

8.  Two new point mutations at A2062 associated with resistance to 16-membered macrolide antibiotics in mutant strains of Mycoplasma hominis.

Authors:  P M Furneri; G Rappazzo; M P Musumarra; P Di Pietro; L S Catania; L S Roccasalva
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

9.  Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage.

Authors:  A Tait-Kamradt; T Davies; M Cronan; M R Jacobs; P C Appelbaum; J Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

10.  Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA.

Authors:  S Douthwaite; L H Hansen; P Mauvais
Journal:  Mol Microbiol       Date:  2000-04       Impact factor: 3.501

View more
  35 in total

1.  In vitro subminimum inhibitory concentrations of macrolide antibiotics induce macrolide resistance in Mycoplasma pneumoniae.

Authors:  G Ou; Y Liu; Y Tang; X You; Y Zeng; J Xiao; L Chen; M Yu; M Wang; C Zhu
Journal:  Hippokratia       Date:  2015 Jan-Mar       Impact factor: 0.471

2.  Molecular characterization of resistance to macrolides in Bartonella henselae.

Authors:  Silpak Biswas; Didier Raoult; Jean-Marc Rolain
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively.

Authors:  D Gruson; S Pereyre; H Renaudin; A Charron; C Bébéar; C M Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation.

Authors:  Miyuki Morozumi; Keiko Hasegawa; Reiko Kobayashi; Nagako Inoue; Satoshi Iwata; Haruo Kuroki; Naohisa Kawamura; Eiichi Nakayama; Takeshi Tajima; Kouichi Shimizu; Kimiko Ubukata
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

5.  Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.

Authors:  Yang Liu; Xinyu Ye; Hong Zhang; Xiaogang Xu; Wanhua Li; Demei Zhu; Minggui Wang
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

Review 6.  Mycoplasma pneumoniae from the Respiratory Tract and Beyond.

Authors:  Ken B Waites; Li Xiao; Yang Liu; Mitchell F Balish; T Prescott Atkinson
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

7.  Multilocus variable-number tandem-repeat analysis-confirmed emergence of a macrolide resistance-associated mutation in Mycoplasma pneumoniae during macrolide therapy for interstitial pneumonia in an immunocompromised child.

Authors:  Sébastien Hantz; Fabien Garnier; Olivia Peuchant; Céline Menetrey; Alain Charron; Marie-Cécile Ploy; Cécile Bébéar; Sabine Pereyre
Journal:  J Clin Microbiol       Date:  2012-07-18       Impact factor: 5.948

8.  In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains.

Authors:  Jørgen Skov Jensen; Prabhavathi Fernandes; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

9.  Ribosomal Mutations Conferring Macrolide Resistance in Legionella pneumophila.

Authors:  Ghislaine Descours; Christophe Ginevra; Nathalie Jacotin; Françoise Forey; Joëlle Chastang; Elisabeth Kay; Jerome Etienne; Gérard Lina; Patricia Doublet; Sophie Jarraud
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

10.  Mutations Associated with Decreased Susceptibility to Seven Antimicrobial Families in Field and Laboratory-Derived Mycoplasma bovis Strains.

Authors:  Kinga M Sulyok; Zsuzsa Kreizinger; Enikő Wehmann; Inna Lysnyansky; Krisztián Bányai; Szilvia Marton; Ákos Jerzsele; Zsuzsanna Rónai; Ibolya Turcsányi; László Makrai; Szilárd Jánosi; Sára Ágnes Nagy; Miklós Gyuranecz
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.